Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.
ADVANCED SEARCH
Log in
Top
Cancer Causes & Control
Published in: Cancer Causes & Control 3/2013

01-03-2013 | Original paper

Serum 25-hydroxyvitamin D and breast cancer in the military: a case–control study utilizing pre-diagnostic serum

Authors: Sharif B. Mohr, Edward D. Gorham, John E. Alcaraz, Christopher I. Kane, Caroline A. Macera, J. Kellogg Parsons, Deborah L. Wingard, Ronald Horst, Cedric F. Garland

Published in: Cancer Causes & Control | Issue 3/2013

Login to get access

Abstract

Purpose

The objective of this study was to ascertain whether a relationship exists between pre-diagnostic serum levels of 25-hydroxyvitamin D (25(OH)D) and risk of breast cancer in young women.

Methods

About 600 incident cases of breast cancer were matched to 600 controls as part of a nested case–control study that utilized pre-diagnostic sera. Logistic regression was used to assess the relationship between serum 25(OH)D concentration and breast cancer risk, controlling for race and age.

Results

According to the conditional logistic regression for all subjects, odds ratios for breast cancer by quintile of serum 25(OH)D from lowest to highest were 1.2, 1.0, 0.9, 1.1, and 1.0 (reference) (p trend = 0.72). After multivariate regression for subjects whose blood had been collected within 90 days preceding diagnosis, odds ratios for breast cancer by quintile of serum 25(OH)D from lowest to highest were 3.3, 1.9, 1.7, 2.6, and 1.0 (reference) (p trend = 0.09).

Conclusions

An inverse association between serum 25(OH)D concentration and risk of breast cancer was not present in the principal analysis, although an inverse association was present in a small subgroup analysis of subjects whose blood had been collected within 90 days preceding diagnosis. Further prospective studies of 25(OH)D and breast cancer risk are needed.
Appendix
Available only for authorised users
Literature
1.
2.
Gorham E, Garland C, Garland F (1989) Acid haze air pollution and breast and colon cancer in 20 Canadian cities. Can J Publ Health 80:96–100
3.
Gorham ED, Garland FC, Garland CF (1990) Sunlight and breast cancer incidence in the USSR. Int J Epidemiol 19(4):820–824PubMedCrossRef
4.
Grant WB (2002) An ecologic study of dietary and solar ultraviolet-B links to breast carcinoma mortality rates. Cancer 94(1):272–281PubMedCrossRef
5.
Garland C, Gorham E, Mohr S, Grant W, Giovannucci E, Lipkin M et al (2007) Vitamin D and prevention of breast cancer: pooled analysis. J Steroid Biochem Mol Biol 103(3–5):708–711PubMedCrossRef
6.
Mohr S, Garland C, Gorham E, Grant W, Garland F (2008) Relationship between low ultraviolet B irradiance and higher breast cancer risk in 107 countries. Breast J 14(3):255–260PubMedCrossRef
7.
Grant WB (2012) Relation between prediagnostic serum 25-hydroxyvitamin D level and incidence of breast, colorectal, and other cancers. J Photochem Photobiol B 101(2):130–136, 3 Nov
8.
Gorham E, Garland F, Garland C (1990) Sunlight and breast cancer incidence in the USSR. Int J Epidemiol 19(4):820–824PubMedCrossRef
9.
Garland C, al. e. (1990) Levels of serum 25-hydroxyvitamin D, 60 individuals aged 60+ years [Graph]. Rancho Bernardo, CA
10.
Garland C, Garland F, Gorham E (1992) Could sunscreens increase melanoma risk? Am J Public Health 82:614–615PubMedCrossRef
11.
Freedman D, Dosemeci M, McGlynn K (2002) Sunlight and mortality from breast, ovarian, colon, prostate, and non-melanoma skin cancer: a composite death certificate based case-control study. Occup Environ Med 59(4):257–262PubMedCrossRef
12.
Looker AC, Dawson-Hughes B, Calvo MS, Gunter EW, Sahyoun NR (2002) Serum 25-hydroxyvitamin D status of adolescents and adults in two seasonal subpopulations from NHANES III. Bone 30(5):771–777PubMedCrossRef
13.
Garland F, Garland C, Gorham E, Young J Jr (1990) Geographic variation in breast cancer mortality in the United States: a hypothesis involving exposure to solar radiation. Prev Med 19:614–622PubMedCrossRef
14.
John E, Schwartz G, Dreon D, Koo J (1999) Vitamin D and breast cancer risk: the NHANES I epidemiologic follow-up study, 1971–1975 to 1992. Cancer Epidemiol Biomark Prev 8:399–406
15.
Shin MH, Holmes MD, Hankinson SE, Wu K, Colditz GA, Willett WC (2002) Intake of dairy products, calcium, and vitamin D and risk of breast cancer. J Natl Cancer Inst 94(17):1301–1311PubMedCrossRef
16.
Rossi M, McLaughlin JK, Lagiou P, Bosetti C, Talamini R, Lipworth L et al (2009) Vitamin D intake and breast cancer risk: a case-control study in Italy. Ann Oncol 20(2):374–378PubMedCrossRef
17.
Robien K, Cutler GJ, Lazovich D (2007) Vitamin D intake and breast cancer risk in postmenopausal women: the Iowa Women’s Health Study. Cancer Causes Control 18(7):775–782PubMedCrossRef
18.
Abbas S, Linseisen J, Chang-Claude J (2007) Dietary vitamin D and calcium intake and premenopausal breast cancer risk in a German case-control study. Nutr Cancer 59(1):54–61PubMedCrossRef
19.
Abbas S, Chang-Claude J, Linseisen J (2009) Plasma 25-hydroxyvitamin D and premenopausal breast cancer risk in a German case-control study. Int J Cancer 124(1):250–255PubMedCrossRef
20.
Abbas S, Linseisen J, Slanger T, Kropp S, Mutschelknauss EJ, Flesch-Janys D et al (2008) Serum 25-hydroxyvitamin D and risk of post-menopausal breast cancer—results of a large case-control study. Carcinogenesis 29(1):93–99PubMedCrossRef
21.
Bertone-Johnson ER, Chen WY, Holick MF, Hollis BW, Colditz GA, Willett WC et al (2005) Plasma 25-hydroxyvitamin D and 1,25-dihydroxyvitamin D and risk of breast cancer. Cancer Epidemiol Biomarkers Prev 14(8):1991–1997PubMedCrossRef
22.
Chlebowski R, Johnson K, Kooperberg C et al (2008) Calcium plus vitamin D supplementation and the risk of breast cancer. JNCI 100:1581–1591PubMedCrossRef
23.
Crew KD, Gammon MD, Steck SE, Hershman DL, Cremers S, Dworakowski E et al (2009) Association between plasma 25-hydroxyvitamin D and breast cancer risk. Cancer Prev Res (Phila) 2(6):598–604CrossRef
24.
Engel P, Fagherazzi G, Boutten A, Dupre T, Mesrine S, Boutron-Ruault MC et al (2010) Serum 25(OH) vitamin D and risk of breast cancer: a nested case-control study from the French E3N cohort. Cancer Epidemiol Biomarkers Prev 19(9):2341–2350PubMedCrossRef
25.
Green AK, Hankinson SE, Bertone-Johnson ER, Tamimi RM (2010) Mammographic density, plasma vitamin D levels and risk of breast cancer in postmenopausal women. Int J Cancer 127(3):667–674PubMedCrossRef
26.
Lowe LC, Guy M, Mansi JL, Peckitt C, Bliss J, Wilson RG et al (2005) Plasma 25-hydroxy vitamin D concentrations, vitamin D receptor genotype and breast cancer risk in a UK Caucasian population. Eur J Cancer 41(8):1164–1169PubMedCrossRef
27.
Rejnmark L, Tietze A, Vestergaard P, Buhl L, Lehbrink M, Heickendorff L et al (2009) Reduced prediagnostic 25-hydroxyvitamin D levels in women with breast cancer: a nested case-control study. Cancer Epidemiol Biomarkers Prev 18(10):2655–2660PubMedCrossRef
28.
Garland C, Comstock G, Garland F, Helsing K, Shaw E, Gorham E (1989) Serum 25-hydroxyvitamin D and colon cancer: eight-year prospective study. Lancet 2:1176–1178PubMedCrossRef
29.
Tworoger SS, Lee IM, Buring JE, Rosner B, Hollis BW, Hankinson SE (2007) Plasma 25-hydroxyvitamin D and 1,25-dihydroxyvitamin D and risk of incident ovarian cancer. Cancer Epidemiol Biomarkers Prev 16(4):783–788PubMedCrossRef
30.
Garland C, Gorham E, Garland F (2009) Vitamin D for cancer prevention: global perspective. Ann Epidemiol 19(7):468–483
31.
Freedman DM, Chang SC, Falk RT, Purdue MP, Huang WY, McCarty CA et al (2008) Serum levels of vitamin D metabolites and breast cancer risk in the prostate, lung, colorectal, and ovarian cancer screening trial. Cancer Epidemiol Biomarkers Prev 17(4):889–894PubMedCrossRef
32.
McCullough ML, Stevens VL, Patel R, Jacobs EJ, Bain EB, Horst RL et al (2009) Serum 25-hydroxyvitamin D concentrations and postmenopausal breast cancer risk: a nested case control study in the Cancer Prevention Study-II Nutrition Cohort. Breast Cancer Res 11(4):R64PubMedCrossRef
33.
Almquist M, Bondeson AG, Bondeson L, Malm J, Manjer J (2010) Serum levels of vitamin D, PTH and calcium and breast cancer risk-a prospective nested case-control study. Int J Cancer Journal international du cancer 127(9):2159–2168, 1 Nov
34.
Eliassen AH, Spiegelman D, Hollis BW, Horst RL, Willett WC, Hankinson SE (2011) Plasma 25-hydroxyvitamin D and risk of breast cancer in the Nurses’ Health Study II. Breast Cancer Res BCR 13(3):R50
35.
Mohr SB, Gorham ED, Alcaraz JE, Kane CJ, Macera CA, Parsons JK, et al (2011) Serum 25-hydroxyvitamin D and prevention of breast cancer: pooled analysis. Anticancer Res 31(9):2939–2948, Sep
36.
Yin L, Grandi N, Raum E, Haug U, Arndt V, Brenner H (2012) Meta-analysis: serum vitamin D and breast cancer risk. Eur J Cancer 46(12):2196–2205, Aug
37.
Gandini S, Boniol M, Haukka J, Byrnes G, Cox B, Sneyd MJ, et al (2012) Meta-analysis of observational studies of serum 25-hydroxyvitamin D levels and colorectal, breast and prostate cancer and colorectal adenoma. Int J Cancer 128(6):1414–1424, 15 Mar
38.
Chen P, Hu P, Xie D, Qin Y, Wang F, Wang H (2010) Meta-analysis of vitamin D, calcium and the prevention of breast cancer. Breast Cancer Res Treatment 121(2):469–477, Jun
39.
Rubertone MV, Brundage JF (2002) The Defense Medical Surveillance System and the Department of Defense serum repository: glimpses of the future of public health surveillance. Am J Public Health 92(12):1900–1904PubMedCrossRef
40.
Ersfeld DL, Rao DS, Body JJ, Sackrison JL Jr, Miller AB, Parikh N et al (2004) Analytical and clinical validation of the 25 OH vitamin D assay for the LIAISON automated analyzer. Clin Biochem 37(10):867–874PubMedCrossRef
41.
Wagner D, Hanwell HE, Vieth R (2009) An evaluation of automated methods for measurement of serum 25-hydroxyvitamin D. Clin Biochem 42(15):1549–1556PubMedCrossRef
42.
Carter GD, Carter R, Jones J, Berry J (2004) How accurate are assays for 25-hydroxyvitamin D? Data from the international vitamin D external quality assessment scheme. Clin Chem 50(11):2195–2197PubMedCrossRef
43.
Mantel N (1963) Chi square tests with one degree of freedom; extensions of the Mantel-Haenszel procedure. J Am Stat Assoc 58:690–700
44.
Bluff JE, Brown NJ, Reed MW, Staton CA (2008) Tissue factor, angiogenesis and tumour progression. Breast Cancer Res BCR 10(2):204
45.
Grant WB (2011) Effect of interval between serum draw and follow-up period on relative risk of cancer incidence with respect to 25-hydroxyvitamin D level: Implications for meta-analyses and setting vitamin D guidelines. Dermato-Endocrinology 3(3):199–204PubMed
46.
Merck Manual of Diagnosis and Therapy (2003) Breast disorders: cancer. In: Robert S, Porter M (ed). Merck Publishing Group, Whitehouse Station
47.
van den Brandt PA, Spiegelman D, Yaun SS, Adami HO, Beeson L, Folsom AR, et al (2000) Pooled analysis of prospective cohort studies on height, weight, and breast cancer risk. Am J Epidemiol 152(6):514–527, 15 Sep
48.
Pandey S, Maheshwari A, Bhattacharya S (2010) The impact of female obesity on the outcome of fertility treatment. J Hum Reprod Sci 3(2):62–67PubMedCrossRef
49.
Gesink Law DC, Maclehose RF, Longnecker MP (2007) Obesity and time to pregnancy. Hum Reprod 22(2):414–420, Feb
50.
Nolte R, Franckowiak SC, Crespo CJ, Andersen RE (2002) U.S. military weight standards: what percentage of U.S. young adults meet the current standards? Am J Med 113(6):486–490PubMedCrossRef
51.
Welsh J (2004) Vitamin D and breast cancer: insights from animal models. Am J Clin Nutr 80(6 Suppl):1721S–1724SPubMed
52.
Eisman J, Martin T, MacIntyre I, Mosely J (1979) 1,25-dihydroxyvitamin D3 receptor in breast cancer cells. Lancet 2:1335–1336PubMedCrossRef
53.
Pendas-Franco N, Gonzalez-Sancho JM, Suarez Y, Aguilera O, Steinmeyer A, Gamallo C et al (2007) Vitamin D regulates the phenotype of human breast cancer cells. Differentiation 75(3):193–207PubMedCrossRef
54.
Wang Q, Lee D, Sysounthone V, Chandraratna RAS, Christakos S, Korah R et al (2001) 1,25-dihydroxyvitamin D3 and retinoic acid analogues induce differentiation in breast cancer cells with function- and cell-specific additive effects. Breast Cancer Res Treat 67(2):157–168PubMedCrossRef
55.
Janowsky EC, Lester GE, Weinberg CR, Millikan RC, Schildkraut JM, Garrett PA et al (1999) Association between low levels of 1,25-dihydroxyvitamin D and breast cancer risk. Public Health Nutr 2(3):283–291PubMedCrossRef
56.
Hiatt RA, Krieger N, Lobaugh B, Drezner MK, Vogelman JH, Orentreich N (1998) Prediagnostic serum vitamin D and breast cancer. J Natl Cancer Inst 90(6):461–463PubMedCrossRef
57.
Friedenreich CM (2012) Physical activity and breast cancer: review of the epidemiologic evidence and biologic mechanisms. Recent Results Cancer Res 188:125–139
58.
Anderson LN, Cotterchio M, Kirsh VA, Knight JA (2011) Ultraviolet sunlight exposure during adolescence and adulthood and breast cancer risk: a population-based case-control study among Ontario women. Am J Epidemiol 174(3):293–304, 9 Jun
Metadata
Title
Serum 25-hydroxyvitamin D and breast cancer in the military: a case–control study utilizing pre-diagnostic serum
Authors
Sharif B. Mohr
Edward D. Gorham
John E. Alcaraz
Christopher I. Kane
Caroline A. Macera
J. Kellogg Parsons
Deborah L. Wingard
Ronald Horst
Cedric F. Garland
Publication date
01-03-2013
Publisher
Springer Netherlands
Published in
Cancer Causes & Control / Issue 3/2013
Print ISSN: 0957-5243
Electronic ISSN: 1573-7225
DOI
https://doi.org/10.1007/s10552-012-0140-6

Other articles of this Issue 3/2013

Cancer Causes & Control 3/2013 Go to the issue

Original paper

An examination of sexual orientation group patterns in mammographic and colorectal screening in a cohort of U.S. women

Original paper

Risk factors for primary lung cancer among never smokers by gender in a matched case–control study

Original paper

Anthropometric characteristics and risk of lymphoid and myeloid leukemia in the European Prospective Investigation into Cancer and Nutrition (EPIC)

Original paper

HBV infection increases the risk of pancreatic cancer: a meta-analysis

Original Paper

The modifying effect of patient location on stage-specific survival following colorectal cancer using geosurvival models

Original paper

Diabetes mellitus as a risk factor for gastrointestinal cancers among postmenopausal women
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine
Image Credits